Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 9, Issue 1
January 14 2025
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Control of antigen-independent T-cell migration after HSCT
Motoko Koyama
View Articletitled, Control of antigen-independent T-cell migration after HSCT
Back from (BTKi) holiday
Clinical Trials & Observations
Danielle M. Brander,Andrea Sitlinger
View Articletitled, Back from (BTKi) holiday
AIHA and rituximab: time for Pneumocystis prophylaxis?
Clinical Trials & Observations
Dennis Lund Hansen,Henrik Frederiksen
View Articletitled, AIHA and rituximab: time for <em>Pneumocystis</em> prophylaxis?

ADVANCES SNAPSHOT

Factor XI inhibitors: a new class of anticoagulants
Jean M. Connors
View Articletitled, Factor XI inhibitors: a new class of anticoagulants

CLINICAL TRIALS AND OBSERVATIONS

Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study
Clinical Trials & Observations
Luke Maese,Mignon L. Loh,Mi Rim Choi,Shirali Agarwal,Etsuko Aoki,Yali Liang,Tong Lin,Suzette Girgis,Cuiping Chen,Shane Roller,Vijayalakshmi Chandrasekaran,Robert Iannone,Lewis B. Silverman,Elizabeth A. Raetz,Rachel E. Rau
View Articletitled, Recombinant <em>Erwinia</em> asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study
Supplemental data
Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial
Clinical Trials & Observations
Jennifer Lachey,Christopher Rovaldi,Suresh Bobba,Jared Tur,Harveen Natarajan,Ben Snyder,Jasbir Seehra
View Articletitled, Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trial
Supplemental data

GENE THERAPY

Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel
Clinical Trials & Observations
Adil Mirza,Mona-Lisa Ritsert,Gloria Tao,Himal Thakar,Stephan Lobitz,Sabine Heine,Leila Koscher,Matthias Dürken,Anita Schmitt,Michael Schmitt,Petra Pavel,Sascha Laier,Donate Jakoby,Johann Greil,Joachim Kunz,Andreas Kulozik
View Articletitled, Gene therapy in transfusion-dependent non-β<sup>0</sup>/β<sup>0</sup> genotype β-thalassemia: first real-world experience of beti-cel
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow
Joshua Lykins,Isabelle C. Becker,Virginia Camacho,Hammodah R. Alfar,JoonWoo Park,Joseph Italiano,Sidney W. Whiteheart
View Articletitled, Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow
Supplemental data
Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment
Kehan Ren,Ermin Li,Inci Aydemir,Yijie Liu,Xu Han,Honghao Bi,Pan Wang,Kara Tao,Amy Ji,Yi-Hua Chen,Jing Yang,Madina Sukhanova,Peng Ji
View Articletitled, Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment
Supplemental data

LYMPHOID NEOPLASIA

Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACE
Vincent Camus,Mathieu Viennot,Pierre-Julien Viailly,Fanny Drieux,Elena-Liana Veresezan,Victor Bobée,Vinciane Rainville,Elodie Bohers,Pierre Sesques,Corinne Haioun,Eric Durot,Michael Bayaram,Cédric Rossi,Laurent Martin,Dominique Penther,Sophie Kaltenbach,Julie Bruneau,Jérôme Paillassa,Olivier Tournilhac,Nicolas Gower,Alexandre Willaume,Chloé Antier,Loïc Renaud,Emilie Lévêque,Pierre Decazes,Stéphanie Becker,David Tonnelet,Philippe Gaulard,Hervé Tilly,Thierry Jo Molina,Alexandra Traverse-Glehen,Marie Donzel,Philippe Ruminy,Fabrice Jardin
View Articletitled, Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′RACE
Supplemental data
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
Yannis K. Valtis,Sean Devlin,Roni Shouval,Kai Rejeski,Magdalena Corona,Alejandro Luna De Abia,Alfredo Rivas-Delgado,Efrat Luttwak,Giulio Cassanello,Ivan Landego,Heiko Schöder,Akshay Bedmutha,Alexander Boardman,Gunjan L. Shah,Michael Scordo,Miguel-Angel Perales,Gilles Salles,M. Lia Palomba,Urvi A. Shah,Jae H. Park
View Articletitled, Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
Supplemental data
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
Amneet Bajwa,Qiuhong Zhao,Marcus Geer,Chenyu Lin,James Westholder,Joseph Maakaron,Monalisa Ghosh,David Frame,Ahmed Galal,Justin Tossey,Nausheen Ahmed,Evandro Bezerra,Nathan Denlinger,Marcos de Lima,Narendranath Epperla,Paolo Caimi,Timothy Voorhees
View Articletitled, Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis

MYELOID NEOPLASIA

CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Erin Jeremy,Esthela Artiga,Sara Elgamal,Carolyn Cheney,Dalen Eicher,Kevan Zalponik,Shelley Orwick,Charlene Mao,Ronni Wasmuth,Bonnie Harrington,Allison Mustonen,Peter Beshay,Patrick Halley,Carlos Castro,Katie Williams,Zachary Hing,Timothy Chen,Christopher Lucas,Nicholas J. Vantangoli,Rosa Lapalombella,Nicole Grieselhuber,Xiaokui Mo,Erin Hertlein,Natarajan Muthusamy,Bethany L. Mundy-Bosse,John C. Byrd,Karilyn T. Larkin
View Articletitled, CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Supplemental data
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
Clinical Trials & Observations
Sandra Castaño-Díez,Mònica López-Guerra,Inés Zugasti,Xavier Calvo,Felicitas Isabel Schulz,Alejandro Avendaño,Elvira Mora,José Falantes,Gemma Azaceta,Mariam Ibáñez,Tzu Chen,Cristina Notario,Neus Amer,Laura Palomo,Helena Pomares,Jordi Vila,Teresa Bernal del Castillo,Carlos Jiménez-Vicente,Daniel Esteban,Francesca Guijarro,José Álamo,Albert Cortés-Bullich,Víctor Torrecillas-Mayayo,Ana Triguero,Lucía Mont-de Torres,Ester Carcelero,Aina Cardús,Ulrich Germing,Beate Betz,Maria Rozman,Leonor Arenillas,Lurdes Zamora,María Díez-Campelo,Blanca Xicoy,Jordi Esteve,Marina Díaz-Beyá
View Articletitled, AML typical mutations (<em>CEBPA</em>, <em>FLT3</em>, <em>NPM1</em>) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
Supplemental data

PLASMA CELL DISORDERS

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
Grace M. Ferri,Cenk Yildirim,Nhan V. Do,Mary Brophy,Joseph S. Park,Nikhil C. Munshi,Nathanael R. Fillmore,Camille V. Edwards
View Articletitled, Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Respiratory phenotype and health care utilization patterns by adults with sickle cell disease
Atu Agawu,Nii Nortey,Charleen Jacobs,Alexis Zebrowski,Michelle P. Lin,Jeffrey Glassberg
View Articletitled, Respiratory phenotype and health care utilization patterns by adults with sickle cell disease
Supplemental data
Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study
Clinical Trials & Observations
Yoann Zadro,Margaux Lafaurie,Marc Michel,Maryse Lapeyre-Mestre,Guillaume Moulis
View Articletitled, Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study
Supplemental data

THROMBOSIS AND HEMOSTASIS

Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis
Nikoletta Pechlivani,Basmah Alsayejh,Mansour Almutairi,Katie Simmons,Thembaninkosi Gaule,Fladia Phoenix,Noppadol Kietsiriroje,Sreenivasan Ponnambalam,Cédric Duval,Robert A.S. Ariëns,Christian Tiede,Darren C. Tomlinson,Ramzi A. Ajjan
View Articletitled, Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis
Supplemental data
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding
Matthew C. Sims,Magdalena Gierula,Jonathan C. Stephens,Alex Tokolyi,Luca Stefanucci,Elodie Persyn,Luanluan Sun,Janine H. Collins,Emma E. Davenport,Emanuele Di Angelantonio,Kate Downes,Michael Inouye,Dirk S. Paul,Will Thomas,Alexander Tolios,Willem H. Ouwehand,Nicholas S. Gleadall,James T. B. Crawley,Adam S. Butterworth,Mattia Frontini,Josefin Ahnström
View Articletitled, The common VTE-protective G haplotype of <em>F5</em> increases factor V-short, TFPI function, and risk of bleeding
Supplemental data
Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid
Derek S. Sim,Meenal Shukla,Cornell R. Mallari,José A. Fernández,Xiao Xu,Doug Schneider,Maxine Bauzon,Terry W. Hermiston,Laurent O. Mosnier
View Articletitled, Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid
Supplemental data

TRANSPLANTATION

Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease
Madelyn Espinosa-Cotton,Sayed Shahabuddin Hoseini,Ileana C. Miranda,John Herrick,Nai-Kong V. Cheung
View Articletitled, Targeting T cells with tetravalent bispecific antibodies for the treatment of graft-versus-host disease
Supplemental data
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow
Kai Zhao,Jieqing Zhu,Sarah Rosenberger,Meng Zhou,Warren D. Shlomchik
View Articletitled, Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow
Supplemental data

RESEARCH LETTERS

Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
Fiona C. Brown,Xin Wang,Richard Birkinshaw,Chong Chyn Chua,Thomas Morley,Sila Kasapgil,Giovanna Pomilio,Piers Blombery,David C. S. Huang,Peter Czabotar,Salvatore F. Priore,Guang Yang,Martin Carroll,Andrew H. Wei,Alexander E. Perl
View Articletitled, Acquired <em>BCL2</em> variants associated with venetoclax resistance in acute myeloid leukemia
Supplemental data
COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
Francesco Autore,Andrea Visentin,Marina Deodato,Candida Vitale,Eugenio Galli,Alberto Fresa,Rita Fazzi,Alessandro Sanna,Jacopo Olivieri,Ilaria Scortechini,Maria Ilaria Del Principe,Paolo Sportoletti,Idanna Innocenti,Marta Coscia,Alessandra Tedeschi,Livio Trentin,Anna Candoni,Alessandro Busca,Livio Pagano,Luca Laurenti
View Articletitled, COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
Supplemental data
Achieving equitable care in pulmonary embolism: exploring the potential of pulmonary embolism response teams
Clinical Trials & Observations
Lidiya V. Sul,Akiva Rosenzveig,Fahad Alkhalfan,G. Jay Bishop,Pulkit Chaudhury,Leben Tefera
View Articletitled, Achieving equitable care in pulmonary embolism: exploring the potential of pulmonary embolism response teams
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
Lucia Y. Chen,Santiago Thibaud,Saoirse Bodnar,Ajai Chari,Joshua Richter,Hearn Jay Cho,Larysa J. Sanchez,Cesar Rodriguez,Adriana C. Rossi,Shambavi Richard,Samir Parekh,Sundar Jagannath
View Articletitled, MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
Zachary M. Avigan,Saoirse Bodnar,Darren Pan,Jerrel Catlett,Joshua Richter,Larysa J. Sanchez,Cesar Rodriguez,Adriana C. Rossi,Shambavi Richard,Sundar Jagannath,Hearn Jay Cho,Samir Parekh,Santiago Thibaud
View Articletitled, Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
Supplemental data
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Clinical Trials & Observations
Tait D. Shanafelt,Xin Victoria Wang,Curtis A. Hanson,Elisabeth Paietta,Susan O’Brien,Jacqueline Barrientos,Diane F. Jelinek,Esteban Braggio,Jose F. Leis,Cong Christine Zhang,Paul M. Barr,Amanda F. Cashen,Anthony R. Mato,Avina K. Singh,Michael P. Mullane,Richard F. Little,Harry Erba,Richard M. Stone,Mark Litzow,Martin Tallman,Neil E. Kay
View Articletitled, Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Supplemental data

ERRATUM

Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.
View Articletitled, Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. <em>Blood Adv.</em> 2024;8(20):5306-5314.
  • Cover Image

    Cover Image

    issue cover

    Surface rendering of the human-induced pluripotent stem cell–derived bone marrow organoid reveals a self-organized 3D endothelial network (red) interconnected with stromal cells (magenta) and hematopoietic cells (green). See the article by Ren et al.

All Issues

Advertisement intended for health care professionals

IDCH: is it now determined?
PETAL: a global view on R/R T-/NK-lymphoma treatment reality
A telemedicine triage model for infusion center–based management of adult sickle cell pain episodes
Loss of protein C vs protein S results in discrepant thrombotic phenotypes
Evolving racial/ethnic disparities in AML survival in the novel therapy era

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals